A primary study of immunotherapy with carcinoembryonic antigen peptide-pulsed, autologous human cultured dendritic cells in patients with advanced non-small cell lung cancer.
- Author:
Baohui HAN
1
;
Hua ZHONG
;
Xiaohong FAN
;
Guangli FENG
;
Rong LI
;
Leluo GONG
;
Tianqing CHU
;
Wei ZHANG
;
Bo JIN
;
Chunlei SHI
;
Yizhuo ZHAO
;
Huifang SHA
;
Qianggang DONG
;
Meilin LIAO
Author Information
- Publication Type:Journal Article
- From: Chinese Journal of Lung Cancer 2006;9(4):340-344
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUNDDendritic cell (DC)-based immunotherapy is a new approach and effective for some malignant tumors. The aim of this study is to observe the efficacy and toxicity of immunotherapy with carcinoembryonic antigen (CEA) peptide-pulsed DCs in patients with refractory advanced lung cancer.
METHODSLung cancer patients with high CEA expression were enrolled into this project. Autologous DCs were generated from patients' plastic-adherent peripheral blood mononuclear cells and loaded with CEA 5 days later. Cytokine-induced killer cells (CIK) were cultured from non-adherent peripheral blood mononuclear cells. DCs and CIK were transfused to patients. Responses and toxicities were observed.
RESULTSA total of 22 patients with lung cancer received DCs immunotherapy. DCs doses were 2.5×10⁶-9.6×10⁷ (5.03×10⁶). CIK doses were 3.4×10⁸-46×10⁸. CD3, CD8, NK and IFN-γ levels obviously increased after treatment (P < 0.05). The 1-year survival rate was 68.2% (15/22). Main toxicities were fever and rash.
CONCLUSIONSDCs-based immunotherapy is feasible and safe to patients with lung cancer.
